Pradaxa

Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age

Ingelheim, Germany:  No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…

Read More »